Review Article

Probiotics, Nuclear Receptor Signaling, and Anti-Inflammatory Pathways

Sonia S. Yoon¹ and Jun Sun¹, ²

¹ Division of Gastroenterology and Hepatology, Department of Medicine, Strong Memorial Hospital, University of Rochester Medical Center, University of Rochester, Rochester, NY 14642, USA
² Department of Microbiology and Immunology, University of Rochester, P.O. Box 646, 601 Elmwood Avenue, Rochester, NY 14642, USA

Correspondence should be addressed to Jun Sun, jun_sun@urmc.rochester.edu

Received 2 February 2011; Revised 28 March 2011; Accepted 19 May 2011

Academic Editor: Genevieve B. Melton-Meaux

Copyright © 2011 S. S. Yoon and J. Sun. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

There is increased investigation of the human microbiome as it relates to health and disease. Dysbiosis is implicated in various clinical conditions including inflammatory bowel disease (IBD). Probiotics have been explored as a potential treatment for IBD and other diseases. The mechanism of action for probiotics has yet to be fully elucidated. This paper discusses novel mechanisms of action for probiotics involving anti-inflammatory signaling pathways. We highlight recent progress in probiotics and nuclear receptor signaling, such as peroxisome-proliferator-activated receptor gamma (PPARγ) and vitamin D receptor (VDR). We also discuss future areas of investigation.

1. Introduction

Probiotics are ingestible microorganisms with health benefits. Increased interest in the intestinal microbiome and its effect on health and disease is evidenced by the concomitant increase in peer-reviewed clinical trials investigating probiotics as therapy since 1999 [1]. Studies of the various signaling pathways involved in the response to bacteria and inflammation have led to a more detailed understanding of mechanisms and actions of probiotics. This paper discusses progress in understanding how probiotics contribute to intestinal mucosal function, particularly in relation to anti-inflammatory signaling pathways.

2. Intestinal Microflora

The intestinal microflora, as a whole, serves important functions in metabolism, intestinal epithelial cell function and health, immunity, and inflammatory signaling [2, 3]. Recently, there has been increasing interest in the role of the intestinal microflora and its total genetic composition, together referred to as the microbiome in the development, maintenance, and perpetuation of various clinical conditions, both intestinal and extraintestinal.

Dysbiosis has been implicated in various clinical conditions including atopy, irritable bowel syndrome (IBS), colorectal cancer, alcoholic liver disease in animal and human studies, obesity and other metabolic disorders, and chronic inflammatory diseases such as IBD [4–11]. Decreased diversity of the intestinal microbiota was seen in fecal samples obtained from children who subsequently developed allergic disease [6, 7]. Altered microbiota composition in colon cancer patients when compared to patients with normal colonoscopies and in patients with IBS compared to unaffected patients has also been demonstrated [5, 9]. Alcohol feeding resulted in enteric bacterial overgrowth in a mouse model [8]. The role of the microbiota in obesity has been extensively studied and carefully reviewed in the literature [12, 13]. Microbial composition in IBD patients with ulcerative colitis (UC) or Crohn’s disease (CD) as compared to unaffected individuals has been studied and shows decreased diversity [4, 14–19]. This altered microflora may have significant implications for the intestinal milieu, with as yet incompletely understood effects. The pathogenesis of IBD...
likely involves a combination of factors including intestinal dysbiosis in conjunction with environmental factors in a genetically susceptible host [20].

Based on the concept of a dysregulated or dysfunctional microbiota in disease, various methods to attenuate the effects of an altered microbiome have been attempted.

3. Probiotics

“Probiotics” were first described in the literature by Lilly and Stillwell in 1965 as growth-promoting factors produced by certain microorganisms [21] although it may have been described as early as 1908 [22]. Recently, probiotics were defined as “live organisms which, when consumed in adequate amounts as part of food, confer a health benefit on the host” (Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria (October 2001), “Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria”, Food and Agriculture Organization of the United Nations, World Health Organization). The mechanisms of action of probiotics include immune modulation, direct effect on commensal and pathogenic bacteria to inhibit infection and restore homeostasis, and modification of pathogenic toxins and host products [23]. The efficacy of probiotics in various clinical conditions both in the pediatric and adult patient population has been extensively studied and carefully reviewed [1, 19, 24–32].

Rectal infusion of normal stool via enemas to treat pseudomembranous colitis has been described as early as 1958 [70]. Infusion of stool via nasogastric tube to the small intestine or via colonoscopy to the colon for CDAD has also been described and shows high response rates [71–74]. A recent study showed that fecal bacteriotherapy was effective in relief of clinical symptoms in a patient with recurrent CDAD and that this was accompanied by the repopulation of the diseased intestinal microbiota with beneficial species that were diminished pretreatment [75]. Other methods to supply live, nonpathogenic organisms to the intestinal microbiota in AAD and CDAD include orally administered probiotics. The efficacy of various probiotic formulations in AAD and CDAD has been extensively studied and carefully reviewed [1]. A recent study showed that the probiotics *Lactobacillus acidophilus* and *Lactobacillus casei* were well tolerated and effective in reducing the risk of the development of AAD and CDAD [76]. The utility of the probiotic yeast *Saccharomyces boulardii* for a variety of conditions including traveler’s diarrhea, enteral nutrition-associated diarrhea, AAD, and CDAD has been investigated, and according to a recent meta-analysis, strong evidence exists for advocating its use in traveler’s diarrhea and AAD [77]. Recent trials using *Bifidobacterium bifidum* and *Saccharomyces boulardii* demonstrated improved clinical IBS symptoms and quality of life [78, 79], and several reviews of the evidence for the utility of probiotics in IBS have been published [80–82].

For IBD therapy, treatment with different strains of probiotics has shown varied results. Small trials have shown promise for probiotic use in the induction and maintenance of remission in UC. VSL#3 has been shown to be safe and effective in the treatment of acute mild to moderately active UC [83]. Patients with mild to moderate UC unresponsive to conventional therapy achieved a combined induction remission/response rate of 77% with treatment with VSL#3 [84]. *E. coli* Nissle 1917 was found to be effective and equivalent to mesalazine in maintaining remission in UC [85]. In another study, *Lactobacillus rhamnosus* GG (LGG) was equivalent to mesalazine in the maintenance of remission in UC, however, appeared to be more effective in prolonging the relapse-free time [86]. Evidence also exists for the role of probiotics in prophylaxis of pouchitis after surgery in UC patients as well as induction of remission in chronic pouchitis [87, 88].

Studies of probiotic use in induction and maintenance of remission and prevention of postoperative recurrence in CD have been less consistent than those for UC. A small study of LGG for the prevention of recurrence after surgery in CD did not show any improvement over placebo [89]; however, *Saccharomyces boulardii* appears useful in maintaining remission in CD [90, 91]. The progress in the use of probiotics for IBD has been carefully reviewed [92, 93]; however, there remains a relative lack of well-designed, large, randomized, placebo-controlled trials.

Several barriers exist to advocating broad use of probiotics in clinical practice, not least of which is the considerable heterogeneity in the experimental designs with respect to species and strains of probiotics and the various animal models utilized [94]. Although clinical trials examining the role of probiotics in the treatment and/or prevention of AAD, CDAD, IBD including UC, CD, and pouchitis, necrotizing enterocolitis, infectious gastroenteritis, radiation-induced enteritis, and colitis, IBS and various atopic diseases have been reported [1, 24, 25, 28, 29, 31, 87, 95–97]; in many cases, results have been inconsistent, and large, well-designed trials are lacking. An additional complicating factor pertains to issues of quality control. Determining whether a commercially available probiotic actually contains the live organisms it purports to contain and determining if there is rational selection of component probiotic strains in “cocktails” are issues that must be considered [22]. Future research to refine techniques to accurately identify “normal” and “diseased” microbiota and to further elucidate the specific effects and mechanisms of actions of individual probiotic strains will aid in optimizing therapeutic efficacy.

4. Mechanisms for Probiotics in Anti-Inflammation

There has been and continues to be considerable research in delineating the underlying mechanisms by which probiotics exert their beneficial effects. The mechanisms regulating the function of probiotics are very diverse. It is well accepted that probiotics use distinct cellular and molecular mechanisms, including blocking pathogenic bacterial effects, regulating immune responses, and altering intestinal epithelial homeostasis by promoting cell survival, enhancing barrier function, and stimulating protective responses [32].
Table 1 outlines representative publications on probiotic mechanisms of actions. The probiotic-host interaction is complex and further complicated by the fact that certain probiotic effects appear to be species and strain specific. Different probiotics have been shown to exert both pro-inflammatory [98] and anti-inflammatory effects on dendritic cells [99]. A recent study demonstrated that the anti-inflammatory effect of certain lactobacilli is via NOD2-mediated signaling [100]. NOD2/CARD15 is a member of a superfamily of genes involved in intracellular bacterial recognition and has been identified as an important susceptibility gene for CD [101, 102]. The authors speculate that the inconsistent clinical results of lactobacilli use in patients with CD may be related to a relative deficiency of NOD2. Probiotic effect on the innate immune responsive pathways including toll-like receptor (TLR), nuclear factor kappa B (NF-κB), mitogen-activated protein kinase (MAPK), c-Jun NH2-terminal kinase (JNK) has been extensively investigated (Table 1). Activation of specific TLRs also appears to be species specific [47, 48]. The action of E. coli Nissle 1917 on Caco-2 cells was found to be mediated by flagellin possibly via a TLR pathway [103]. The probiotic-induced effect on the NF-κB signaling pathway is well represented in the literature and is generally characterized by inhibition (Table 1).

Defective epithelial barrier function has been implicated in IBD and can predict relapse during clinical remission [104–109]. One way by which probiotics have been shown exert their action is by stabilizing tight junctions (TJs) and enhancing barrier function of intestinal epithelial cells (Table 1).

Abnormal STAT/suppressor of cytokine signaling (SOCS) signaling has been demonstrated in CD patients [110], and probiotics are also shown to modulate the JAK-STAT signaling in human placental trophoblast cells [111]. Increasing evidence further demonstrates that metabolism, xenobiotics, and nuclear receptor signaling are involved in the action of probiotics [67, 68].

Induction of heat shock proteins (HSPs) and endogenous antimicrobial peptides (defensins) via activation of NF-κB, MAPK, and JNK has also been linked to probiotic action [35, 41, 43]. Since defensins are implicated in the pathogenesis of IBD, increased expression by probiotics provides a possible mechanism for clinical efficacy seen in certain IBD patients and deserves further study.

5. Defensins and Nuclear Receptor Signaling

Defensins are a class of endogenous antimicrobial peptides involved in innate immunity which is highly evolutionarily conserved and represents a primary line of defense against various microbial pathogens [112–114]. Antimicrobial peptides are widely distributed throughout the animal and plant kingdom, and despite their evolutionary heritage, remain effective antimicrobial agents [114]. This is due, in large part, to their mechanism of action involving membrane disruption and pore formation, which is not easily exploited by pathogens to confer resistance [112–115]. Important antimicrobial peptides in humans include defensins, cathelicidins, lysozymes, and other antimicrobial antiproteases [116]. There are three known defensin subfamilies; α and β defensins are expressed mainly in immune cells and epithelial cells while the θ defensin is found mainly in immune cells of the Rhesus macaque [117, 118]. In the gastrointestinal tract, β defensin expression is seen in multiple sites, whereas α defensin expression is largely in the small intestine [119]. In the uninfamed colon, human β defensin 1 is the predominant defensin and human β defensin 2 and 3 are induced with inflammation or infection [120]. In mice lacking functional cryptidins (murine α defensins), increased survival and virulence of orally administered bacteria were seen and intestinal peptide preparations had decreased antimicrobial activity [121].

The possible role of a deficiency in defensins in the pathogenesis of IBD has been proposed [116, 122]. The Paneth cells of the small intestine are the major source of endogenous antimicrobials, including α defensins [102]. In addition, The Paneth cells have been shown to express NOD2 [123]. In patients with ileal CD, human α defensin 5 and 6 production is reduced, and this effect is magnified in those patients with a concomitant NOD2 mutation [124]. For β defensins, CD patients with colonic disease exhibit normal levels of β defensin 2 and 3 whereas UC patients have increased levels, suggesting a role of failure of β defensin induction in the pathogenesis of CD [125]. Constitutive human β defensin 1 expression is reduced in CD patients with colonic involvement independent of inflammation, and recently, the maintenance of constitutive β defensin expression was shown to be activated by the nuclear receptor peroxisome-proliferator-activated receptor gamma (PPARγ) [122].

Further contributing to the effect of a defensin deficiency in the pathogenesis of IBD may be the diminished diversity of the intestinal microbiota seen in IBD patients. The interaction of commensal bacteria with antimicrobial peptide synthesis is not well understood; however, it has been suggested that commensal bacteria provide chronic stimulation of epithelial cells to produce antimicrobial peptides at levels sufficient to kill microbial pathogens [114, 126].

Probiotics, but not fecal isolates, have been shown to induce human β defensin 2 in intestinal epithelial cells [41, 42]. Wehkamp et al. and Schlee et al. have reported that NF-κB and activator protein-1 (AP-1) mediate induction of human β defensin 2 in intestinal epithelial cells by the probiotic E. coli Nissle 1917 and VSL#3 [41, 42].

Interestingly, nuclear receptors are known to regulate the expressions of defensins [122, 127]. Nuclear receptors represent a class of intracellular transcription factors activated by ligands which can directly interact with DNA; as a result, nuclear receptors play significant roles in the regulation of metabolic, reproductive, developmental, and immune processes [128–131]. Nuclear receptors regulate transcriptional activity by several distinct mechanisms, including “ligand-dependent transactivation, ligand-independent repression, and ligand-dependent transrepression” although the range of transcriptional activities of each nuclear receptor varies and even the transcriptional effects of a single nuclear receptor may be cell specific [132]. A detailed discussion
| Involved pathways | Probiotics | In vitro system | In vivo system | Summary | Ref. |
|-------------------|------------|----------------|--------------|---------|-----|
| NF-κB             | (i) *L. casei* Shirota (LcS) | (i) THP-1 | (i) Rat | (i) L-lactic acid and LcS culture supernatant inhibited NF-κB activation, TNF-α mRNA expression increase, and TNF-α protein secretion in cells treated with lipopolysaccharide (LPS) | [33] |
| NF-κB             | (i) LGG | (i) CaCo-2 | | (i) LGG reduced TNF-α-induced NF-κB translocation, lessened decrease in IκBα, reduced TNFα-induced interleukin (IL)-8 production | [34] |
| NF-κB             | (i) VSL3# | (i) YAMC | | (i) VSL3# inhibited the proinflammatory NF-κB pathway and induced the expression of cytoprotective heat shock proteins (HSPs) in intestinal epithelial cells | [35] |
| NF-κB             | (i) *L. plantarum* (LP) (ii) Murine dendritic cells | (i) YAMC, RAW264.7 | | (i) LP-conditioned media (CM) inhibited the chymotrypsin-like activity of the proteasome, NF-κB binding activity as well as the degradation of IκBα | [36] |
| NF-κB             | (i) LP-L2 | (i) CaCo-2 | | (i) Caco-2 cells preincubated with LP-L2 showed attenuation of monocyte chemotactic protein-1 (MCP-1) protein production and mRNA expression and also prevented IκBα degradation in TNF-α-stimulated Caco-2 cells | [37] |
| NF-κB             | (i) *L. casei* (Lc) (ii) CaCo-2 | (i) HEK-293T | | (i) Lc downregulated the transcription of genes encoding proinflammatory effectors and adherence molecules induced by invasive *S. flexneri* resulting in anti-inflammation mediated by the inhibition of the NF-κB pathway | [38] |
| NF-κB             | (i) *B. lactis* | (i) Mode-K (ii) MEF | | (i) *B. lactis* activates NF-κB RelA and p38 MAPK phosphorylation in IEC lines | [39] |
| NF-κB MAPK (ERK1/2/p38/JNK) | (i) *S. boulardii* (Sb) | (i) T84 | (i) NIH Mice | (i) *In vivo*, Sb protected mice from *Salmonella enterica* serovar-Typhimurium-(ST-) induced death and prevented hepatic bacterial translocation (ii) In T84 human colorectal cancer cells, Sb incubation abolished *Salmonella* invasion, preserved barrier function, and decreased ST-induced IL-8 synthesis (iii) Sb had an inhibitory effect on ST-induced activation of the MAPKs, extracellular regulated kinase (ERK) 1/2, p38 and JNK, and NF-κB | [40] |
| NF-κB MAPK (p38/ERK) SAPK/JNK | (i) *E. coli* Nissle 1917 (ECN) (ii) *L. fermentum* (iii) *L. acidophilus* (La) (iv) *Pediococcus pentosaceus* (v) *L. paracasei* (vi) VSL3# | (i) CaCo-2 | | (i) CaCo-2 cells treated with probiotic had peak of human β defensins-2 (hBD-2) mRNA expression at 6 h incubation (ii) Promoter activation via probiotics was abolished with the deletion of NF-κB- and activator-protein-1- (AP-1-) binding sites on the hBD-2 promoter (iii) Induction of hBD-2 depends on MAPK, ERK 1/2, p38, and c-Jun N-terminal kinase (JNK), to varying degrees | [41] |
### Table 1: Continued.

| Involved pathways | Probiotics | In vitro system | In vivo system | Summary | Ref. |
|-------------------|------------|-----------------|---------------|---------|------|
| **NF-κB**<br>SAPK/JNK | (i) ECN<br>(ii) Various *E. coli* strains<br>(iii) Various *Lactobacillus* strains | (i) CaCo-2 | | (i) Active and heat-inactivated ECN and several other probiotic bacteria potently induced hBD-2 in intestinal epithelial cells<br>(ii) hBD-2 promoter activation was abolished by mutation of the two NF-κB sites in the hBD-2 promoter upon treatment with ECN<br>(iii) ECN-induced activation of AP-1 may be regulated by JNK kinase pathway | [42] |
| **SAPK/JNK**<br>MAPK (p38) | (i) LGG | (i) YAMC | | (i) LGG-CM induced Hsp25 and Hsp72 in time- and concentration-dependent manner<br>(ii) LGG-CM-induced HSP72 induction was blocked by the Inhibitors of p38 and JNK | [43] |
| **Epidermal growth factor receptor (EGFR)** | (i) Sb | (i) HT-29 | (i) APC min | | [44] |
| **TLR NF-κB**<br>MAPK (p38) | (i) LGG<br>(ii) *B. longum* | (i) HT-29<br>(ii) T84 | | (i) Commensal-origin DNA enhanced expression of TLR9 in HT-29 and T84 cells<br>(ii) This was associated with attenuation of TNF-α-induced NF-κB activation by reducing IκBα degradation and p38 phosphorylation<br>(iii) LGG DNA decreased the TNF-α-induced reduction in transepithelial electrical resistance (TER) | [45] |
| **TLR** | (i) *LP BFE 1685*<br>(ii) LGG | (i) HT-29 | | (i) HT29 cells incubated with lactobacilli showed upregulation of TLR2 and TLR9 transcription levels<br>(ii) Protein expression levels of TLR2 and TLR5 were enhanced | [46] |
| **TLR** | (i) VSL#3 | (i) Mice | | (i) Intragastric administration of gamma-irradiated probiotics significantly ameliorated the severity of DSS-induced colitis in TLR2- and TLR4-deficient mice but not in TLR9-deficient mice | [47] |
| **TLR** | (i) ECN<br>(ii) Wild-type (WT), TLR2-/-TLR4-knockout mice | (i) Mice | | (i) ECN decreased colitis and proinflammatory cytokine secretion in WT but not TLR2- or TLR4-knockout mice<br>(ii) ECN resulted in reduction of interferon (IFN)-γ secretion in TLR2 knockout<br>(iii) Cytokine secretion was almost undetectable and not modulated by ECN in TLR-4-knockout mice<br>(iv) Increased TLR2 and TLR4 protein expression and NF-κB activity via TLR2 and TLR4 was seen with ECN and human T-cell coculture | [48] |
| Involved pathways | Probiotics | In vitro system | In vivo system | Summary | Ref. |
|-------------------|------------|----------------|---------------|---------|------|
| MAPK (p38/ERK)   | (i) LP     | (i) Mice peritoneal macrophages | | (i) LP strongly induced IL-10 and weakly induced IL-12; Lc strongly induced IL-12 and weakly induced IL-10 | [49] |
|                   | (ii) Lc    |                |               | (ii) LP, compared to Lc, demonstrated more rapid and strong activation of MAPKs, especially of ERK | |
|                   |            |                |               | (iii) Blocking LP-induced ERK activation resulted in decreased IL-10 production and increased IL-12 production | |
|                   |            |                |               | (iv) Combined stimulation with LP and Lc resulted in synergistic induction of IL-10 production; this was triggered by the key factors: cell wall teichoic acid and lipoteichoic acids | |
|                   |            |                |               | (v) Teichoic-acid-induced IL-10 production was mediated by TLR2-dependent ERK activation | |
| MAPK (p38/ERK)   | (i) LGG    | (i) CaCo-2     |               | (i) LGG-produced soluble proteins (p40 and p75) diminished the hydrogen-peroxide-induced decrease in TER and increase in inulin permeability and induced increase in membrane translocation of protein kinase C (PKC) beta I, PKC epsilon, and level of phospho-ERK1/2 in the detergent-insoluble fractions | [50] |
| Tight junctions (TJ) |            |                |               | (ii) LGG-produced soluble proteins (p40 and p75) prevented hydrogen-peroxide-induced redistribution of occludin, zonula occludens (ZO)-1, E-cadherin, and beta-catenin from intercellular junctions and their dissociation from the detergent-insoluble fractions | |
|                   |            |                |               | (iii) p40- and p75-mediated reduction of hydrogen-peroxide-induced tight junction disruption and inulin permeability was attenuated by U0126 (a MAP kinase inhibitor) | |
| MAPK (p38/ERK)   | (i) B. infantis | (i) IL-10, IL-1 deficient mice | (i) T84 | (i) B. infantis-conditioned medium (BiCM) increased TER, ZO-1, and occludin expression and decreased claudin-2 expression; this was associated with increased phospho-ERK and decreased phospho-p38 | [51] |
| Tj                |            | (i) IL-10, IL-1 deficient mice | | (ii) TNF-α- and IFN-γ-induced drops in TER and rearrangement of TJ proteins were prevented by BiCM | |
|                   |            | (i) T84        |               | (iii) Inhibition of ERK attenuated the protection from TNF-α and IFN-γ and prevented BiCM-induced increase in TER | |
|                   |            | (i) CaCo-2     |               | (iv) In vivo, oral BiCM reduced colonic permeability, in IL-10-deficient mice, long-term BiCM decreased colonic and splenic IFN-γ secretion, attenuated inflammation, and normalized colonic permeability | |
| TJ                | (i) LP MB452 | (i) CaCo-2     |               | (i) LP MB452 increased TER across Caco-2 cell monolayers in dose-dependent manner | [52] |
|                   |            |                |               | (ii) Altered expression of several tight-junction-related genes (including occludin and associated plaque proteins) was seen in response to LP MB452 | |
|                   |            |                |               | (iii) LP MB452 caused changes in gene expression levels of tubulin and proteasome | |
|                   |            |                |               | (iv) LP MB452-treated cells showed increased fluorescence intensity of the four tight junction proteins when compared to untreated controls | |
| Involved pathways | Probiotics | In vitro system | In vivo system | Summary | Ref. |
|------------------|------------|----------------|---------------|---------|-----|
| TJ PKC           | (i) LP     | (i) CaCo-2     |               | (i) Unconjugated bilirubin (UCB) caused decreased PKC activity, serine phosphorylated occluding, and ZO-1 levels (ii) High concentrations of UCB caused cytotoxicity and decreased TER (iii) Treatment with LP mitigated the effects of UCB on TER and apoptosis, prevented aberrant expression and rearrangement of TJ proteins, and partially restored PKC activity and serine phosphorylated TJ protein levels | [53] |
| TJ               | (i) LP DSM2648 (ii) La | (i) CaCo-2 | (i) Human | (i) LP DSM 2648 reduced the deleterious effect of *Escherichia coli* (enteropathogenic *E. coli* (EPEC)) O127:H6 (E2348/69) on TER and adherence with simultaneous or prior coculture compared with EPEC incubation alone | [54] |
| TJ TLR           | (i) LP     | (i) CaCo-2     | (i) Human | (i) B. *bifidum* decreased the incidence of necrotizing enterocolitis (NEC), normalized IL-6, mucin-3, and Tff3 levels in the ileum of NEC rats, and normalized the expression and localization of TJ and adherens junction (AJ) proteins in the ileum compared with animals with NEC (ii) B. *bifidum* did not affect reduced mucin-2 production in the NEC rats | [55] |
| TJ               | (i) VSL#3  | (i) BALB/c mice |               | (i) VSL#3 treatment prevented the increase in epithelial permeability in acute colitis, decrease in expression and redistribution of occludin, ZO-1, and claudin-1, claudin-3, claudin-4, and claudin-5, and increase of epithelial apoptotic ratio | [57] |
| TJ               | (i) Lr     | (i) Mice       |               | (i) Pretreatment with combination of Lr and La significantly prevented decrease in the membrane-bound ATPases and reduced expression of tight junction proteins in the membrane | [58] |
| TJ               | (i) B. *lactis* 420 (ii) B. *lactis* HN019 (iii) La NCFM (iv) *L. salivarius* Ls-33 | (i) CaCo-2 | | (i) B. *lactis* 420 and *Escherichia coli* O157:H7 (EHEC) supernatant had opposite effects in tight junction integrity; B. *lactis* 420 supernatant protected the tight junctions from EHEC-induced damage when administered before EHEC supernatant (ii) EHEC and probiotics had reverse effects upon cyclo-oxygenase expression | [59] |
| TJ               | (i) ECN    | (i) BALB/c mice |               | (i) ECN colonization of gnotobiotic mice resulted in upregulation of ZO-1 mRNA and protein levels in IECs (ii) ECN administration reduced loss of body weight and colon shortening in DSS-treated mice (iii) ECN inoculation ameliorates the infiltration of the colon with leukocytes | [60] |
| TJ PKC           | (i) ECN    | (i) T84        |               | (i) EPEC with ECN coinubation: addition of ECN after EPEC infection restored barrier integrity and abolished barrier disruption (ii) ECN altered the expression, distribution of ZO-2 protein and of distinct PKC isoforms; ZO-2 expression was increased in parallel to its redistribution towards the cell boundaries (iii) ECN induces restoration of a disrupted epithelial barrier; this is transmitted by PKCzeta silencing and ZO-2 redistribution | [61] |
| Involved pathways | Probiotics | In vitro system | In vivo system | Summary                                                                                                                                                                                                 | Ref. |
|-------------------|------------|----------------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| TJ                | (i) LGG    | (i) MDCK-1, T84|               | (i) EHEC-induced decrease in electrical resistance and the increase in barrier permeability assays were attenuated by probiotic pretreatment<br> (ii) LGG protected epithelial monolayers against EHEC-induced redistribution of claudin-1 and ZO-1 proteins<br> (iii) Heat-inactivated LGG did not affect EHEC binding or disruption of barrier function | [62]|
| JAK/STAT MAPK (p38/ERK) | (i) *Streptococcus thermophilus*<br>(ii) La<br>(i) HT29/cl.19A<br>(ii) Caco-2, |               |               | (i) *Streptococcus thermophilus* (ST)/La or the commensal *Bacteroides thetaiotaomicron* (BT) prevented the TNF-α- and IFN-γ-induced reduction in TER and increase in epithelial permeability<br> (ii) ST/La or BT prevented IFN-γ inhibition of agonist-stimulated chloride secretion<br> (iii) ST/La or BT restoration of Cl(−) secretion was blocked by inhibitors of p38 MAPK, ERK1, 2, and PI3K<br> (iv) ST/La pretreatment reversed the IFN-γ-induced downregulation of the cystic fibrosis transmembrane conductance regulator (CFTR) and the NKCC1 cotransporter<br> (v) The effects of ST/La or BT on TER and permeability were potentiated by a Janus kinase (JAK) inhibitor but not by p38, ERK1, 2, or PI3K inhibition<br> (vi) Reduced activation of suppressor of cytokine signaling (SOCS)3 and STAT1,3 was seen only in probiotic-treated epithelial cells exposed to cytokines | [63]|
| JAK/STAT NF-κB    | (i) LcS    | (i) RAW264.7<br>(ii) LI-LPMC<br>(iii) UC-PBMC | (i) SAMPI/Yit mice | (i) LcS improved chronic ileitis in SAMPI/Yit mice<br> (ii) LcS improved murine chronic colitis, and this was associated with decreased IL-6 production by large intestinal lamina propria mononuclear cells (LI-LPMCs) and downregulation of proinflammatory cytokines such as IL-6 and IFN-γ production in LPMC<br> (iii) IL-6 release in LPS-activated LI-LPMC, RAW264.7, and ulcerative colitis-peripheral blood mononuclear cells (UC-PBMCs) was inhibited by LcS-derived polysaccharide-peptidoglycan complex (PSPG)<br> (iv) In lipopolysaccharide- (LPS-) stimulated LI-LPMC and RAW264.7 cells, LcS inhibited the production of IL-6; other strains of *Lactobacillus* did not<br> (v) Nuclear translocation of NF-κB was downregulated by LcS | [64] |
| Involved pathways                  | Probiotics                          | In vitro system | In vivo system | Summary                                                                                                                                                                                                 | Ref. |
|-----------------------------------|-------------------------------------|-----------------|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| JAK/STAT                          | (i) *Lactobacillus helveticus* R0052 | (i) Intestine 407 (ii) HEP-2 (iii) Caco-2 |               | (i) After EHEC O157:H7 infection, STAT-1 activation was reduced compared to uninfected cells (ii) Preincubation with *L. helveticus* R0052 (but not boiled *L. helveticus* R0052, an equal concentration of viable *Lr* R0011, or surface-layer proteins) followed by EHEC infection abrogated disruption of IFN-γ-STAT-1 signaling | 65   |
| SAPK/JNK MAPK (p38) NF-κB          | (i) *S. cerevisiae* UFMG 905        | (i) Mice        |               | (i) After *Salmonella* challenge, *S. cerevisiae* 905 inhibited weight loss and increased survival rate (ii) Levels of proinflammatory cytokines were decreased, and activation of mitogen-activated protein kinases (p38 and JNK, but not ERK1/2), NF-κB, and AP-1 was modulated by *S. cerevisiae* 905 | 66   |
| Lipid/Xenobiotic                  | (i) VSL#3                           | (i) IL-10 KO    |               | (i) Probiotics resulted in downregulation of CXCL9, CXCL10, CCL5, T-cell activation and IRGM (ii) Probiotic treatment decreased the number of CCL5+ CD3+ double-positive T cells consistent with reduction in integrins and upregulated galectin2 (iii) Lipid- and PPAR-signaling-associated genes were also upregulated (iv) Altered microbial diversity was noted in probiotic-treated mice (v) Inflammation in IL10-KO mice showed differential regulation of various signaling pathways (inflammatory, nuclear receptor, lipid, and xenobiotic) | 67   |
| Metabolism/ Glucose Uptake        | (i) *L. gasseri* (ii) *L. amylovorus* (iii) *L. gallinarum* (iv) *L. johnsonii* | (i) CaCo-2      |               | (i) Exposure to bacteria-free supernatants of La cultured in chemically defined media (CDM) with 110 mM fructose increased glucose accumulation; exposure to a suspension of the bacteria had no effect (ii) Heat-denaturing the supernatant diminished the increase in glucose accumulation (iii) Supernatants prepared with anaerobic culture of *L. gasseri, L. amylovorus, L. gallinarum, and L. johnsonii* in the CDM with fructose increased glucose accumulation | 68   |
| Reactive Oxygen Species (ROS) NF-κB | (i) *Lr*                            | (i) FHs74Int    | (i) C57BL/6J  | (i) LGG induced ROS generation in intestinal epithelia *in vitro* and *in vivo* (ii) Increased glutathione (GSH) oxidation and cullin-1 deneddylation was seen in the intestines of mice fed LGG, showing local ROS generation and the resultant Ubc12 inactivation (iii) Prefeeding LGG prevented TNF-α-induced activation of intestinal NF-κB | 69   |
of nuclear receptors and their mechanisms of action is beyond the scope of this article; however, further discussion of two nuclear receptors (peroxisome-proliferator-activated receptor gamma (PPARγ) and vitamin D receptor (VDR)) with putative roles in inflammation is warranted.

PPARγ is a member of a class of nuclear receptors that form obligate heterodimers with the retinoid X receptor (RXR) [129]. The PPAR family has been shown to affect various cellular functions including “adipocyte differentiation, fatty-acid oxidation, and glucose metabolism” [129]. PPARγ is highly expressed in the large intestine [133], and its activation has been shown to be protective in animal models of colitis [134, 135]. Decreased PPARγ expression in UC patients has been shown [136], and the anti-inflammatory compound 5-aminosalicylic acid (5-ASA) commonly utilized in IBD therapy was shown to be a PPARγ agonist, thereby establishing a possible mechanism by which it exerts its anti-inflammatory effects [137]. PPARγ also plays a role in the maintenance of “constitutive epithelial expression of a subset of β defensins in the colon” [122].

6. Vitamin D and Vitamin D Receptor (VDR)

Vitamin D receptor (VDR) is a nuclear receptor that mediates most known functions of 1,25-dihydroxyvitamin D (1,25(OH)2D3), the active form of vitamin D [138]. VDR heterodimerizes with RXR once VDR is activated by 1,25(OH)2D3. VDR binds to the vitamin D response element in the target gene promoter to regulate gene transcription [139]. VDR downstream target genes include antimicrobial peptides such as cathelicidin and β defensin.

VDR is critical in regulating intestinal homeostasis by preventing pathogenic bacterial invasion, inhibiting inflammation, and maintaining cell integrity [140–145]. Vitamin D directly modulates the T-cell receptor (TCR) [146], and vitamin D has also been shown to downregulate the expression of proinflammatory cytokines and have regulatory effects on autophagy and various immune cells including T cells, B cells, macrophages, dendritic cells, and epithelial cells [147, 148]. It has been reported that 1,25(OH)2D3 suppresses the development of IBD in animal models [149]. Deficiency of 1,25(OH)2D3 has been reported in patients with IBD [150, 151], and, recently, using a novel vitamin D bioavailability test, vitamin D deficiency or insufficiency was seen in more than 70% of patients with quiescent CD [152].

Given the diverse immune functions of vitamin D, deficient levels may have important implications for the development and maintenance of intestinal homeostasis. A possible role of vitamin D status and VDR signaling in regulating the effects of intestinal microflora in other conditions such as asthma and obesity has been suggested [100]. While present literature has primarily focused on elucidating the immunoregulatory effects of vitamin D, there is a paucity of data on the status and function of VDR [147]. In addition, probiotic-induced modulation of anti-inflammatory VDR signaling in colitis remains virtually unexplored.

Recent studies indicate that VDR−/− mice have increased bacterial loading in the intestine [145, 153]. Our microarray data found that VDR signaling responds to pathogenic Salmonella in intestinal colitis in vivo [154]. Data from a recent study demonstrate that bacterial stimulation, both commensal and pathogenic, regulates VDR expression and location and that VDR negatively regulates bacterial-induced intestinal NF-κB activation [153]. In general, probiotic-induced nuclear receptor signaling is not well characterized. The probiotic VSL3# was associated with nuclear receptor signaling in the IL10−/− colitis model [67]. Nuclear receptors have been shown to negatively regulate bacterial-stimulated NF-κB activity in intestinal epithelium [153, 155]. Our recent data show probiotic treatment is able to enhance VDR expression and activity in the host. An increase in VDR expression and a concomitant increase in cathelicidin mRNA in cultured intestinal epithelial cells when treated with Lactobacillus plantarum were seen [156]. We used a probiotic monoassociated pig model to assess the probiotic effect on VDR expression in vivo and found intestinal VDR increased significantly after probiotic colonization compared to the ex-germ-free pig. Furthermore, our unpublished data indicate that probiotics did not inhibit inflammation in mice lacking VDR.

The presence of VDR in various tissues along with its ability to exert diverse actions in differentiation, growth, and anti-inflammation sets the stage for exploitation of VDR ligands for the treatment of various inflammatory conditions [157, 158]. Although the potential importance of VDR as a therapeutic target has been appreciated [159], no approach to date has safely and effectively altered VDR’s activity. Hence, understanding VDR’s contribution to probiotic-induced anti-inflammation may provide significant insight in the pathogenesis of inflammatory conditions such as IBD, and thereby, guide the development of novel treatments. Further investigation of the complex interplay of nuclear receptors, defensins, probiotics, and inflammatory pathways may provide significant insight into the mechanisms of action of probiotics in anti-inflammation.

7. Current Problems and Future Directions

The individual diversity of the intestinal microflora underscores the difficulty of identifying the entire human microbiota and poses barriers to this field of research. In addition, it is apparent that the actions of probiotics are species and strain specific [19]. It is also apparent that even a single strain of probiotic may exert its actions via multiple, concomitant pathways. Current investigation into the mechanism of action of specific probiotics has focused on probiotic-induced changes in the innate immune functions involving TLRs and its downstream systems including NF-κB, JAK-STAT, MAPK, and SAPK/JNK pathways. Future research on novel mechanisms of action for probiotics involving nuclear receptor signaling, including PPARγ and VDR, is needed. With evolving knowledge, effective probiotic therapy will be possible in the future.

Abbreviations
AAD: Antibiotic-associated diarrhea
AP-1: Activator protein-1
CD: Crohn’s disease

10 Gastroenterology Research and Practice
References

[1] L. V. McFarland, “Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections,” *Anaerobe*, vol. 15, no. 6, pp. 274–280, 2009.

[2] A. S. Neish, “Microbes in gastrointestinal health and disease,” *Gastroenterology*, vol. 136, no. 1, pp. 65–80, 2009.

[3] W. S. Garrett, J. I. Gordon, and L. H. Glimcher, “Homeostasis and inflammation in the Intestine,” *Cell*, vol. 140, no. 6, pp. 859–870, 2010.

[4] M. Joossens, G. Huys, M. Cnockaert et al., “Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives,” *Gut*, vol. 60, no. 5, pp. 631–637, 2011.

[5] I. Sobhani, J. Tap, F. Roudot-Thoraval et al., “Microbial dysbiosis in colorectal cancer (CRC) patients,” *PLoS ONE*, vol. 6, no. 1, Article ID e16393, 2011.

[6] Y. M. Sjögren, M. C. Jenmalm, M. F. Böttcher, B. Björkstén, and E. Sverremark-Ekström, “Altered early infant gut microbiota in children developing allergy up to 5 years of age,” *Clinical and Experimental Allergy*, vol. 39, no. 4, pp. 518–526, 2009.

[7] B. Björkstén, P. Naaber, E. Sepp, and M. Mikelsaar, “The intestinal microflora in allergic Estonian and Swedish 2-year-old children,” *Clinical and Experimental Allergy*, vol. 29, no. 3, pp. 342–346, 1999.

[8] A. W. Yan, D. E. Fouts, J. Brandl et al., “Enteric dysbiosis associated with a mouse model of alcoholic liver disease,” *Hepatology*, vol. 53, no. 1, pp. 96–105, 2011.

[9] A. Kassinen, L. Krogius-Kurikka, H. Mäkivuokko et al., “The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects,” *Gastroenterology*, vol. 133, no. 1, pp. 24–33, 2007.

[10] R. E. Ley, P. J. Turnbaugh, S. Klein, and J. I. Gordon, “Microbial ecology: human gut microbes associated with obesity,” *Nature*, vol. 444, no. 7122, pp. 1022–1023, 2006.

[11] M. Vijay-Kumar, J. D. Aitken, F. A. Carvalho et al., “Metabolic syndrome and altered gut microbiota in mice lacking toll-like receptor 5,” *Science*, vol. 328, no. 5975, pp. 228–231, 2010.

[12] R. E. Ley, “Obesity and the human microbiome,” *Current Opinion in Gastroenterology*, vol. 26, no. 1, pp. 5–11, 2010.

[13] R. E. Ley, F. Bäckhed, P. Turnbaugh, C. A. Lozupone, R. D. Knight, and J. I. Gordon, “Obesity alters gut microbiota ecology,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 31, pp. 11070–11075, 2005.

[14] C. Manichanh, L. Rigottier-Gois, E. Bonnada et al., “Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach,” *Gut*, vol. 55, no. 2, pp. 205–211, 2006.

[15] D. N. Frank, A. L. S. Amand, R. A. Feldman, E. C. Boedeker, N. Harpaz, and N. R. Pace, “Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 34, pp. 13780–13785, 2007.

[16] M. P. Conte, S. Schippa, I. Zamboni et al., “Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease,” *Gut*, vol. 55, no. 12, pp. 1760–1767, 2006.

[17] R. B. Sartor, “Microbial influences in inflammatory bowel diseases,” *Gastroenterology*, vol. 134, no. 2, pp. 577–594, 2008.

[18] C. D. Packey and R. B. Sartor, “Interplay of commensal and pathogenic bacteria, genetic mutations, and immunoregulatory defects in the pathogenesis of inflammatory bowel diseases,” *Nature Reviews Gastroenterology and Hepatology*, vol. 13, no. 7, pp. 399–409, 2016.

Acknowledgments

This work was supported by the National Institutes of Health (DK075386-0251, R03DK089010-01) and the IDEAL award from the New York State’s Empire State Stem Cell Board (N09G-279) to J. Sun.
diseases,” *Journal of Internal Medicine*, vol. 263, no. 6, pp. 597–606, 2008.

[19] C. Reiff and D. Kelly, “Inflammatory bowel disease, gut bacteria and probiotic therapy,” *International Journal of Medical Microbiology*, vol. 300, no. 1, pp. 25–33, 2010.

[20] R. B. Sartor, “Mechanisms of disease: pathogenesis of crohn’s disease and ulcerative colitis,” *Nature Clinical Practice Gastroenterology and Hepatology*, vol. 3, no. 7, pp. 390–407, 2006.

[21] D. M. Lilly and R. H. Stillwell, “Probiotics: growth-promoting factors produced by microorganisms,” *Science*, vol. 147, no. 3659, pp. 747–748, 1965.

[22] E. M. Quigley, “Probiotics in gastrointestinal disorders,” *Hospital Practice*, vol. 38, no. 4, pp. 122–129, 2010.

[23] T. A. Oelschlaeger, “Mechanisms of probiotic actions— a review,” *International Journal of Medical Microbiology*, vol. 300, no. 1, pp. 57–62, 2010.

[24] B. G. Spyropoulos, E. P. Misiakos, C. Fotiadis, and C. N. Stoidis, “Antioxidant properties of probiotics and their protective effects in the pathogenesis of radiation-induced enteritis and colitis,” *Digestive Diseases and Sciences*, vol. 52, no. 2, pp. 285–294, 2010.

[25] F. Yan and D. B. Polk, “Probiotics as functional food in the treatment of diarrhea,” *Current Opinion in Clinical Nutrition and Metabolic Care*, vol. 9, no. 6, pp. 717–721, 2006.

[26] K. Madsen, “Probiotics in critically ill patients,” *Journal of Clinical Gastroenterology*, vol. 42, supplement 3, pp. S116–S118, 2008.

[27] C. I. Fotiadis, C. N. Stoidis, B. G. Spyropoulos, and E. D. Zografos, “Role of probiotics, prebiotics and synbiotics in chemoprevention for colorectal cancer,” *World Journal of Gastroenterology*, vol. 14, no. 42, pp. 6453–6457, 2008.

[28] R. Francavilla, V. Miniello, A. M. Magistà et al., “A randomized controlled trial of lactobacillus GG in children with functional abdominal pain,” *Pediatrics*, vol. 126, no. 6, pp. e1445–e1452, 2010.

[29] D. W. Thomas, F. R. Greer, J. J. S. Bhatia et al., “Clinical report—probiotics and prebiotics in pediatrics,” *Pediatrics*, vol. 126, no. 6, pp. 1217–1231, 2010.

[30] D. Damaskos and G. Kolios, “Probiotics and prebiotics in inflammatory bowel disease: microflora ‘on the scope’,” *British Journal of Clinical Pharmacology*, vol. 65, no. 4, pp. 453–467, 2008.

[31] A. Tursi, G. Brandimarte, A. Papa et al., “Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study,” *American Journal of Gastroenterology*, vol. 105, no. 10, pp. 2218–2227, 2010.

[32] C. Vanderpool, F. Yan, and D. B. Polk, “Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases,” *Inflammatory Bowel Diseases*, vol. 14, no. 11, pp. 1585–1596, 2008.

[33] T. Watanabe, H. Nishio, T. Tanigawa et al., “Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid,” *American Journal of Physiology*, vol. 297, no. 3, pp. G506–G513, 2009.

[34] L. Zhang, N. Li, R. Caicedo, and J. Neu, “Alive and dead Lactobacillus rhamnosus GG decrease tumor necrosis factor-α-induced interleukin-8 production in Caco-2 cells,” *Journal of Nutrition*, vol. 135, no. 7, pp. 1752–1756, 2005.

[35] E. O. Petrof, K. Kojima, M. J. Ropeleski et al., “Probiotics inhibit nuclear factor-κB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition,” *Gastroenterology*, vol. 127, no. 5, pp. 1474–1487, 2004.

[36] E. O. Petrof, E. C. Claud, J. Sun et al., “Bacteria-free solution derived from Lactobacillus plantarum inhibits multiple NF-kappaB pathways and inhibits proteasome function,” *Inflammatory Bowel Diseases*, vol. 15, no. 10, pp. 1537–1547, 2009.

[37] B. Wang, J. Li, J. Chen, Q. Huang, N. Li, and J. Li, “Effect of live Lactobacillus plantarum L2 on TNF-α-induced MCP-1 production in Caco-2 cells,” *International Journal of Food Microbiology*, vol. 142, no. 1–2, pp. 237–241, 2010.

[38] M. T. Tien, S. E. Girardin, B. Regnault et al., “Anti-inflammatory effect of Lactobacillus casei on Shigella-infected human intestinal epithelial cells,” *Journal of Immunology*, vol. 176, no. 2, pp. 1228–1237, 2006.

[39] P. A. Ruiz, M. Hoffmann, S. Szczesny, M. Blaut, and D. Haller, “Innate mechanisms for Bifidobacterium lactis to activate transient pro-inflammatory host responses in intestinal epithelial cells after the colonization of germ-free rats,” *Immunology*, vol. 115, no. 4, pp. 441–450, 2005.

[40] F. S. Martins, G. Dalmaso, R. M. E. Arantes et al., “Interaction of Saccharomyces boulardii with Salmonella enterica serovar typhimurium protects mice and modifies TH84 cell response to the infection,” *PLoS ONE*, vol. 5, no. 1, Article ID e9829, 2010.

[41] M. Schlec, J. Harder, B. Kösten, E. F. Stange, J. Wehkamp, and K. Fellermann, “Probiotic lactobacilli and VSL#3 induce enterocyte β-defensin 2,” *Clinical and Experimental Immunology*, vol. 151, no. 3, pp. 528–535, 2008.

[42] J. Wehkamp, J. Harder, K. Wehkamp et al., “NF-κB and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium,” *Infection and Immunity*, vol. 72, no. 10, pp. 5750–5758, 2004.

[43] Y. Tao, K. A. Drabik, T. S. Waypa et al., “Soluble factors from Lactobacillus GG activate MAPKs and induce cytoprotective heat shock proteins in intestinal epithelial cells,” *American Journal of Physiology*, vol. 290, no. 4, pp. C1018–C1030, 2006.

[44] X. Chen, J. Fruehau, J. D. Goldsmith et al., “Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice,” *Gastroenterology*, vol. 137, no. 3, pp. 914–923, 2009.

[45] D. Ghadimi, M. De Vrese, K. J. Heller, and J. Schrezenmeir, “Effect of natural commensal-origin DNA on toll-like receptor 9 (TLR9) signaling cascade, chemokine IL-8 expression, and barrier integrity of polarized intestinal epithelial cells,” *Inflammatory Bowel Diseases*, vol. 16, no. 3, pp. 410–427, 2010.

[46] M. G. Vizoso Pinto, M. Rodriguez Gómez, S. Seifert, B. Watzl, W. H. Holzapfel, and C. M. A. P. Franz, “Lactobacilli stimulate the innate immune response and modulate the TLR expression of HT29 intestinal epithelial cells in vitro,” *International Journal of Food Microbiology*, vol. 133, no. 1–2, pp. 86–93, 2009.

[47] D. Rachmilewitz, K. Katakura, F. Karmeli et al., “Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis,” *Gastroenterology*, vol. 126, no. 2, pp. 520–528, 2004.

[48] A. Grabig, D. Pacilik, C. Guzy et al., “Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways,” *Infection and Immunity*, vol. 74, no. 7, pp. 4075–4082, 2006.

[49] C. I. Fotiadis, C. N. Stoidis, B. G. Spyropoulos, and E. D. Zografos, “Role of probiotics, prebiotics and synbiotics in inflammatory bowel disease, ” *Infectious Diseases and Colonization*, vol. 14, no. 11, pp. 1585–1596, 2008.
prevalent IL-10 production via TLR2-dependent ERK activation in macrophages,” *Journal of Immunology*, vol. 184, no. 7, pp. 3505–3513, 2010.

50. A. Seth, F. Yan, D. B. Polk, and R. K. Rao, “Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism,” *American Journal of Physiology*, vol. 294, no. 4, pp. 2269–2276, 2008.

51. J. B. Ewaschuk, H. Díaz, L. Meddings et al., “Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function,” *American Journal of Physiology*, vol. 295, no. 5, pp. G1025–G1034, 2008.

52. R. C. Anderson, A. L. Cookson, W. C. McNabb et al., “Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation,” *BMC Microbiology*, vol. 10, article 316, 2010.

53. Y. Zhou, H. Qin, M. Zhang et al., “Lactobacillus plantarum inhibits intestinal epithelial barrier dysfunction induced by unconjugated bilirubin,” *British Journal of Nutrition*, vol. 104, no. 3, pp. 390–401, 2010.

54. R. C. Anderson, A. L. Cookson, W. C. McNabb, W. J. Kelly, and N. C. Roy, “Lactobacillus plantarum DSM 2648 is a potential probiotic that enhances intestinal barrier function,” *FEMS Microbiology Letters*, vol. 309, no. 2, pp. 184–192, 2010.

55. J. Karczewski, F. I. Troost, I. Konings et al., “Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier,” *American Journal of Physiology*, vol. 298, no. 6, pp. G851–G859, 2010.

56. L. Khailova, K. Dvorak, K. M. Arganbright et al., “Bifidobacterium bifidum improves intestinal integrity in a rat model of necrotizing enterocolitis,” *American Journal of Physiology*, vol. 297, no. 5, pp. G940–G949, 2009.

57. R. Menningen, K. Nolte, E. Rijcken et al., “Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis,” *American Journal of Physiology*, vol. 296, no. 5, pp. G1140–G1149, 2009.

58. G. Moorthy, M. R. Murali, and S. N. Devaraj, “Lactobacilli facilitate maintenance of intestinal membrane integrity during Shigella dysenteriae 1 infection in rats,” *Nutrition*, vol. 25, no. 3, pp. 350–358, 2009.

59. H. Putaala, T. Salusjärvi, M. Nordström et al., “Effect of four probiotic strains and Escherichia coli O157:H7 on tight junction integrity and cyclo- oxygenase expression,” *Research in Microbiology*, vol. 159, no. 9–10, pp. 692–698, 2008.

60. S. N. Ukena, A. Singh, U. Dringenberg et al., “Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity,” PLoS ONE, vol. 2, no. 12, Article ID e1308, 2007.

61. A. A. Zyrek, C. Cichon, S. Helms, C. Enders, U. Sonnenborn, and M. A. Schmid, “Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCζ redistribution resulting in tight junction and epithelial barrier repair,” *Cellular Microbiology*, vol. 9, no. 3, pp. 804–816, 2007.

62. K. C. Johnson-Henry, K. A. Donato, G. Shen-Tu, M. Gordon-pour, and P. M. Sherman, “Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function,” *Infection and Immunity*, vol. 76, no. 4, pp. 1340–1348, 2008.

63. S. Resta-Lenert and K. E. Barrett, “Probiotics and commensals reverse TNF-α- and IFN-γ-induced dysfunction in human intestinal epithelial cells,” *Gastroenterology*, vol. 130, no. 3, pp. 731–746, 2006.

64. S. Matsumoto, T. Hara, T. Hori et al., “Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the downregulation of pro-inflammatory cytokines in lamina propria mononuclear cells,” *Clinical and Experimental Immunology*, vol. 140, no. 3, pp. 417–426, 2005.

65. N. Jandu, Z. J. Zeng, K. C. Johnson-Henry, and P. M. Sherman, “Probiotics prevent enterohaemorrhagic Escherichia coli O157 : H7-mediated inhibition of interferon-γ-induced tyrosine phosphorylation of STAT-1,” *Microbiology*, vol. 155, no. Pt 2, pp. 531–540, 2009.

66. F. S. Martins, S. D. A. Eliaian, A. T. Vieira et al., “Oral treatment with Saccharomyces cerevisiae strain UFMG 905 modulates immune responses and interferes with signal pathways involved in the activation of inflammation in a murine model of typhoid fever,” *International Journal of Medical Microbiology*, vol. 301, no. 4, pp. 359–364, 2011.

67. C. Reiff, M. Delday, G. Rucklidge et al., “Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease,” *Inflammatory Bowel Diseases*, vol. 15, no. 11, pp. 1721–1736, 2009.

68. A. K. Rooij, Y. Kimura, and R. K. Buddington, “Metabolites produced by probiotic Lactobacilli rapidly increase glucose uptake by Caco-2 cells,” *BMC Microbiology*, vol. 10, article 16, 2010.

69. P. W. Lin, L. E. S. Myers, L. Ray et al., “Lactobacillus rhamnosus blocks inflammatory signaling in vivo via reactive oxygen species generation,” *Free Radical Biology and Medicine*, vol. 47, no. 8, pp. 1205–1211, 2009.

70. B. Eiseman, W. Silen, G. S. Bascom, and A. J. Kauvar, “Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis,” *Surgery*, vol. 44, no. 5, pp. 854–859, 1958.

71. J. Aas, C. E. Gessert, and J. S. Bakken, “Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube,” *Clinical Infectious Diseases*, vol. 36, no. 5, pp. 580–585, 2003.

72. S. E. Persky and L. J. Brandt, “Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoScope,” *American Journal of Gastroenterology*, vol. 95, no. 11, pp. 3283–3285, 2000.

73. S. S. Yoon and L. J. Brandt, “Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoScope: a case series of 12 patients,” *Journal of Clinical Gastroenterology*, vol. 44, no. 8, pp. 562–566, 2010.

74. G. Russell, J. Kaplan, M. Ferraro, and L. C. Michelow, “Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol,” *Pediatrics*, vol. 126, no. 1, pp. e239–e242, 2010.

75. A. Khoruts, J. Dicksved, J. K. Jansson, and M. J. Sadowsky, “Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent clostridium difficile-associated diarrhea,” *Journal of Clinical Gastroenterology*, vol. 44, no. 5, pp. 354–360, 2010.

76. X. W. Gao, M. Mubasher, C. Y. Fang, C. Reifer, and L. E. Miller, “Dose response efficacy of a proprietary probiotic formula of lactobacillus acidophilus CL1285 and lactobacillus casei LBC80R for antibiotic-associated diarrhea and clostridium difficile-associated diarrhea prophylaxis in adult
patients," American Journal of Gastroenterology, vol. 105, no. 7, pp. 1636–1641, 2010.
[77] L. V. McFarland, “Systematic review and meta-analysis of saccharomyces boulardii in adult patients,” World Journal of Gastroenterology, vol. 16, no. 18, pp. 2202–2222, 2010.
[78] S. Guglielmetti, D. Mora, M. Gschwender, and K. Popp, “Randomised clinical trial: bifidobacterium bifidum MIMBB75 significantly alleviates irritable bowel syn-drome and improves quality of life—a double-blind, pla-cebo-controlled study,” Alimentary Pharmacology and Therapeutics, vol. 33, no. 10, pp. 1123–1132, 2011.
[79] C. H. Choi, S. Y. Jo, H. J. Park, S. K. Chang, J.-S. Byeon, and S.-J. Myung, "A randomized, double-blind, placebo-controlled multcenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life," Journal of Clinical Gastroenterology. In press.
[80] G. C. Parkes, J. D. Sanderson, and K. Whelan, “Treating irritable bowel syndrome with probiotics: the evidence,” Proceedings of the Nutrition Society, vol. 69, no. 2, pp. 187–194, 2010.
[81] P. Moayyedi, A. C. Ford, N. J. Talley et al., “The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review,” Gut, vol. 59, no. 3, pp. 325–332, 2010.
[82] D. M. Brenner, M. J. Moeller, W. D. Chey, and P. S. Schoenfeld, “The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review,” American Journal of Gastroenterology, vol. 104, no. 4, pp. 1033–1049, 2009.
[83] A. Sood, V. Midha, G. K. Makharia et al., “The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis,” Clinical Gastroenterology and Hepatology, vol. 7, no. 11, pp. 1202–1209, 2009.
[84] R. Bibiloni, R. N. Fedorak, G. W. Tannock et al., “VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis,” American Journal of Gastroenterology, vol. 100, no. 7, pp. 1539–1546, 2005.
[85] W. Kruis, P. Frié, J. Pokrotnieks et al., “Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine,” Gut, vol. 53, no. 11, pp. 1617–1623, 2004.
[86] M. A. Zocco, L. Z. Dal Verme, F. Cremonini et al., “Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 11, pp. 1567–1574, 2006.
[87] P. Gionchetti, F. Rizzello, U. Helwig et al., “Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial,” Gastroenterology, vol. 124, no. 5, pp. 1202–1209, 2003.
[88] T. Mimura, F. Rizzello, U. Helwig et al., “Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis,” Gut, vol. 53, no. 1, pp. 108–114, 2004.
[89] C. Prantera, M. L. Scribano, G. Falasco, A. Andreoli, and C. Luzzi, “Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG,” Gut, vol. 51, no. 3, pp. 403–409, 2002.
[90] E. Garcia Viléla, M. De Lourdes De Abreu Ferrari, H. Oswaldo Da Gama Torres et al., “Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn’s disease in remission,” Scandinavian Journal of Gastroenterology, vol. 43, no. 7, pp. 842–848, 2008.
[91] M. Guslandi, G. Mezzi, M. Sorghi, and P. A. Testoni, “Saccharomyces boulardii in maintenance treatment of Crohn’s disease,” Digestive Diseases and Sciences, vol. 45, no. 7, pp. 1462–1464, 2000.
[92] J. B. Ewaschuk and L. A. Dieleman, “Probiotics and prebiotics in chronic inflammatory bowel diseases,” World Journal of Gastroenterology, vol. 12, no. 37, pp. 5941–5950, 2006.
[93] C. Hedin, K. Whelan, and J. O. Lindsay, “Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials,” Proceedings of the Nutrition Society, vol. 66, no. 3, pp. 307–315, 2007.
[94] S. C. Ng, A. L. Hart, M. A. Kamm, A. J. Stagg, and S. C. Knight, “Mechanisms of action of probiotics: recent advances,” Inflammatory Bowel Diseases, vol. 15, no. 2, pp. 300–310, 2009.
[95] K. Alfaleh and D. Bassler, “Probiotics for prevention of necro-tizing enterocolitis in preterm infants,” Cochrane Database of Systematic Reviews, no. 1, article CD005486, 2008.
[96] A. Bousvaros, S. Guandalini, R. N. Baldassano et al., “A randomized, double-blind trial of lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn’s disease,” Inflammatory Bowel Diseases, vol. 11, no. 9, pp. 833–839, 2005.
[97] M. Schultz, A. Timmer, H. H. Herfarth, R. B. Sartor, J. A. Vanderhoof, and H. C. Rath, “Lactobacillus GG in inducing and maintaining remission of Crohn’s disease,” BMC Gastroenterology, vol. 4, article 5, 2004.
[98] M. Mohammadzadeh, S. Olson, W. V. Kalina et al., “Lactobacilli active human dendritic cells that skew T cells toward T helper 1 polarization,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 8, pp. 2880–2885, 2005.
[99] A. L. Hart, K. Lammers, P. Brigidi et al., “Modulation of human dendritic cell phenotype and function by probiotic bacteria,” Gut, vol. 53, no. 11, pp. 1602–1609, 2004.
[100] E. M. Fernandez, V. Valenti, C. Rockel et al., “Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide,” Gut, vol. 60, no. 8, pp. 1050–1059, 2011.
[101] M. Chamaillard, S. E. Girardin, J. Viala, and D. J. Philpott, “Nods, nalps and naip: intracellular regulators of bacterial-induced inflammation,” Cellular Microbiology, vol. 5, no. 9, pp. 581–592, 2003.
[102] J. Wehkamp and E. F. Stange, “Is there a role for defensins in IBD?” Inflammatory Bowel Diseases, vol. 14, supplement 2, pp. S85–S87, 2008.
[103] M. Schlee, J. Wehkamp, A. Altenhoefer, T. A. Oelschlaeger, J. A. Vanderhoof, and H. C. Rath, “Lactobacillus GG in children with Crohn’s disease, placebo in addition to standard maintenance therapy for children with Crohn’s disease,” Inflammatory Bowel Diseases, vol. 15, no. 2, pp. 300–310, 2009.
[104] J. B. Ewaschuk and L. A. Dieleman, “Probiotics and prebiotics in chronic inflammatory bowel diseases,” World Journal of Gastroenterology, vol. 12, no. 37, pp. 5941–5950, 2006.
[105] C. Hedin, K. Whelan, and J. O. Lindsay, “Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials,” Proceedings of the Nutrition Society, vol. 66, no. 3, pp. 307–315, 2007.
[106] S. C. Ng, A. L. Hart, M. A. Kamm, A. J. Stagg, and S. C. Knight, “Mechanisms of action of probiotics: recent advances,” Inflammatory Bowel Diseases, vol. 15, no. 2, pp. 300–310, 2009.
[108] I. D. R. Arnott, K. Kingstone, and S. Ghosh, “Abnormal intestinal permeability predicts relapse in inactive Crohn disease,” Scandinavian Journal of Gastroenterology, vol. 35, no. 11, pp. 1163–1169, 2000.

[109] J. Wyatt, H. Vogelsang, W. Hubl, T. Waldhoer, and H. Lochs, “Intestinal permeability and the prediction of relapse in Crohn’s disease,” Lancet, vol. 341, no. 8858, pp. 1437–1439, 1993.

[110] P. Lovato, C. Brender, J. Agnholt et al., “Constitutive STAT3 activation in intestinal T cells from patients with Crohn’s disease,” Journal of Biological Chemistry, vol. 278, no. 19, pp. 16777–16781, 2003.

[111] M. Yeganegi, C. G. Leung, A. Martins et al., “Lactobacillus rhamnosus GR-1-induced IL-10 production in human placental trophoblast cells involves activation of JAK/STAT and MAPK pathways,” Reproductive Sciences, vol. 17, no. 11, pp. 1043–1051, 2010.

[112] A. Giuliani, G. Pirri, and S. F. Nicoletto, “Antimicrobial peptides: an overview of a promising class of therapeutics,” Central European Journal of Biology, vol. 2, no. 1, pp. 1–33, 2007.

[113] H. G. Boman, “Peptide antibiotics and their role in innate immunity,” Annual Review of Immunology, vol. 13, pp. 61–92, 1995.

[114] M. Zasloff, “Antimicrobial peptides of multicellular organisms,” Nature, vol. 415, no. 6870, pp. 389–395, 2002.

[115] B. M. Peters, M. E. Shirliff, and M. A. Jabra-Rizk, “Antimicrobial peptides: primeval molecules or future drugs?” PLoS Pathogens, vol. 6, no. 10, Article ID e1001067, 2010.

[116] J. Wehkamp, E. F. Stange, and K. Fellermann, “Defensin-immunology in inflammatory bowel disease,” Gastroenterologie Clinique et Biologique, vol. 33, supplement 3, pp. S137–144, 2009.

[117] Y. Q. Tang, J. Yuan, G. Osapay et al., “A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated α-defensins,” Science, vol. 286, no. 5439, pp. 498–502, 1999.

[118] A. J. Ouellette and C. L. Bevin, “Paneth cell defensins and innate immunity of the small bowel,” Inflammatory Bowel Diseases, vol. 7, no. 1, pp. 43–50, 2001.

[119] J. Wehkamp, K. Fellermann, K. R. Herrlinger, C. L. Bevin, and E. F. Stange, “Mechanisms of disease: defensins in gastrointestinal diseases,” Nature Clinical Practice Gastroenterology and Hepatology, vol. 2, no. 9, pp. 406–415, 2005.

[120] S. J. Bensinger and P. Tonutono, “Integration of metabolism and inflammation by lipid-activated nuclear receptors,” Nature, vol. 454, no. 7203, pp. 470–477, 2008.

[121] K. Wang and Y. J. Y. Wan, “Nuclear receptors and inflammatory diseases,” Experimental Biology and Medicine, vol. 233, no. 5, pp. 496–506, 2008.

[122] D. J. Mangelsdorf, C. Thummel, M. Beato et al., “The nuclear receptor superfamily: the second decade,” Cell, vol. 83, no. 6, pp. 835–839, 1995.

[123] C. K. Glass and S. Ogawa, “Combinatorial roles of nuclear receptors in inflammation and immunity,” Nature Reviews Immunology, vol. 6, no. 1, pp. 44–55, 2006.

[124] L. Fajas, D. Auboeuf, E. Raspé et al., “The organization, promoter analysis, and expression of the human PPARγ gene,” Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779–18789, 1997.

[125] M. Adachi, R. Kurotani, K. Morimura et al., “Peroxisome proliferator activated receptor γ in colonic epithelial cells protects against experimental inflammatory bowel disease,” Gut, vol. 55, no. 8, pp. 1104–1113, 2006.

[126] J. Wassagañya-Riera, K. Reynolds, S. Martino-Catt et al., “Activation of PPAR γ and δ by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease,” Gastroenterology, vol. 127, no. 3, pp. 777–791, 2004.

[127] L. Dubuquoy, E. Å Jansson, S. Deeb et al., “Impaired expression of peroxisome proliferator-activated receptor γ in ulcerative colitis,” Gastroenterology, vol. 124, no. 5, pp. 1265–1276, 2003.

[128] C. Rousseaux, B. Lefebvre, L. Dubuquoy et al., “Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-γ,” Journal of Experimental Medicine, vol. 201, no. 8, pp. 1205–1215, 2005.

[129] M. R. Haussler, G. K. Whitfield, C. A. Haussler et al., “The nuclear vitamin D receptor: biological and molecular regulatory properties revealed,” Journal of Bone and Mineral Research, vol. 13, no. 3, pp. 325–349, 1998.

[130] S. Kato, “The function of vitamin D receptor in vitamin D action,” Journal of Biochemistry, vol. 127, no. 5, pp. 717–722, 2000.

[131] D. L. Kamen and V. Tangpricha, “Vitamin D and molecular implications of the TLR and VDR partnership,” Trends in Molecular Medicine, vol. 13, no. 3, pp. 117–124, 2007.

[132] A. F. Gambert, N. Borregaard, and H. P. Koefl, “Human cathelicidin antimicrobial peptide (CAMP) gene is a direct
target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3,” *FASEB Journal*, vol. 19, no. 9, pp. 1067–1077, 2005.

[144] J. Kong, Z. Zhang, M. W. Musch et al., “Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier,” *American Journal of Physiology*, vol. 294, no. 1, pp. G208–G216, 2008.

[145] V. Lagishetty, A. V. Misharin, N. Q. Liu et al., “Vitamin D deficiency in mice impairs colonic antibacterial activity and predisposes to colitis,” *Endocrinology*, vol. 151, no. 6, pp. 2423–2432, 2010.

[146] M. R. Von Essen, M. Kongsbak, P. Schjerling, K. Olggaard, N. Ødum, and C. Geisler, “Vitamin D controls T cell antigen receptor signaling and activation of human T cells,” *Nature Immunology*, vol. 11, no. 4, pp. 344–349, 2010.

[147] J. Sun, “Vitamin D and mucosal immune function,” *Current Opinion in Gastroenterology*, vol. 26, no. 6, pp. 591–595, 2010.

[148] S. Wu and J. Sun, “Vitamin D, vitamin D receptor, and macroautophagy in inflammation and infection,” *Discovery Medicine*, vol. 11, no. 59, pp. 325–335, 2011.

[149] M. T. Cantorna, C. Munsick, C. Bemiss, and B. D. Mahon, “1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease,” *Journal of Nutrition*, vol. 130, no. 11, pp. 2648–2652, 2000.

[150] T. A. Sentongo, E. J. Semaaco, N. Stettler, D. A. Piccoli, V. A. Stallings, and B. S. Zemel, “Vitamin D status in children, adolescents, and young adults with Crohn disease,” *American Journal of Clinical Nutrition*, vol. 76, no. 5, pp. 1077–1081, 2002.

[151] M. T. Abreu, Y. Kantorovich, E. A. Vasilaukas et al., “Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn’s disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density,” *Gut*, vol. 53, no. 8, pp. 1129–1136, 2004.

[152] F. A. Farraye et al., “Use of a novel vitamin d bioavailability test demonstrates that vitamin D absorption is decreased in patients with quiescent crohn’s disease,” *Inflammatory Bowel Diseases*.

[153] S. Wu, A. P. Liao, Y. Xia et al., “Vitamin D receptor negatively regulates bacterial-stimulated NF-κB activity in intestine,” *American Journal of Pathology*, vol. 177, no. 2, pp. 686–697, 2010.

[154] X. Liu, R. Lu, Y. Xia, and J. Sun, “Global analysis of the eukaryotic pathways and networks regulated by Salmonella typhimurium in mouse intestinal infection in vivo,” *BMC Genomics*, vol. 11, no. 1, p. 722, 2010.

[155] D. Kelly, J. I. Campbell, T. P. King et al., “Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shutting of PPAR-γ and RelA,” *Nature Immunology*, vol. 5, no. 1, pp. 104–112, 2004.

[156] S. Yoon, S. Wu, and Y. Zhang, “Probiotic regulation of vitamin D receptor in intestinal inflammation,” Oral Presentation DDW, 2011.

[157] E. Gocek and G. P. Studzinski, “Vitamin D and differentiation in cancer Signaling differentiation E. Gocek and G. P. Studzinski,” *Critical Reviews in Clinical Laboratory Sciences*, vol. 46, no. 4, pp. 190–209, 2009.

[158] S. Samuel and M. D. Sitrin, “Vitamin D’s role in cell proliferation and differentiation,” *Nutrition Reviews*, vol. 66, supplement 2, no. 10, pp. S116–S124, 2008.

[159] M. B. Demay, “Mechanism of vitamin D receptor action,” *Annals of the New York Academy of Sciences*, vol. 1068, no. 1, pp. 204–213, 2006.